Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial (Q46675368)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2008

Language	Label	Description	Also known as
English	Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial	scientific article published in March 2008

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

Reinhard G Bretzel

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Ulrike Nuber

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Wolfgang Landgraf

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

David R Owens

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Clare Bradley

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Thomas Linn

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

371

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

9618

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

1073-1084

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of alternative strategies for optimizing glycemia: progress to date

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Is HbA1 Measurement Superfluous in NIDDM?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycosylated hemoglobin in normal subjects and subjects with maturity-onset diabetes. Evidence for a saturable system in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment regimen determines the relationship between depression and glycemic control.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960485-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60485-7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18374840

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46675368&oldid=2125831862"